Skip to main content

Table 2 Clinical outcomes at month 6: patients in remission at month 12 but not month 6

From: Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE)

Mean score (SD) (95 % CI) Patients in SDAI remission at month 12 but not month 6 Patients in CDAI remission at month 12 but not month 6
Abatacept + MTX (n = 36) MTX alone (n = 18) Abatacept + MTX (n = 37) MTX alone (n = 23)
Baseline Month 6 Baseline Month 6 Baseline Month 6 Baseline Month 6
DAS28 6.31 (1.01) 3.17 (1.03) (2.82, 3.52) 5.91 (1.10) 3.22 (1.16) (2.64, 3.79) 6.42 (0.97) 3.17 (1.02) (2.83, 3.51) 6.00 (1.07) 3.34 (1.11) (2.86, 3.82)
SDAI 48.73 (16.05) 11.57 (11.29) (7.75, 15.39) 43.71 (14.77) 11.89 (11.81) (6.02, 17.76) 49.67 (15.68) 11.31 (11.22) (7.57, 15.05) 44.58 (14.58) 12.20 (11.03) (7.42, 16.97)
CDAI 45.68 (14.86) 11.07 (11.18) (7.29, 14.85) 41.17 (14.69) 10.79 (11.34) (5.15, 16.43) 46.44 (14.57) 10.76 (11.12) (7.05, 14.47) 41.69 (13.91) 11.05 (10.65) (6.44, 15.65)
TJC28 17.28 (7.23) 4.17 (5.23) (2.40, 5.94) 15.11 (7.41) 4.06 (5.63) (1.26, 6.86) 17.43 (7.37) 3.97 (5.19) (2.24, 5.70) 15.52 (7.29) 4.26 (5.27) (1.98, 6.54)
SJC28 15.25 (6.15) 3.64 (5.16) (1.89, 5.38) 14.11 (5.71) 3.33 (4.98) (0.86, 5.81) 15.38 (6.09) 3.57 (5.10) (1.87, 5.27) 14.35 (5.42) 3.30 (4.68) (1.28, 5.33)
PGA (0–10 cm VAS) 6.57 (2.47) 2.20 (1.48) (1.70, 2.70) 5.66 (2.87) 1.77 (1.25) (1.14, 2.39) 6.92 (2.29) 2.24 (1.50) (1.74, 2.74) 5.67 (2.82) 1.88 (1.30) (1.32, 2.44)
EGA (0–10 cm VAS) 6.59 (2.02) 1.07 (1.09) (0.70, 1.43) 6.28 (2.12) 1.63 (1.22) (1.03, 2.24) 6.71 (1.87) 0.98 (1.07) (0.62, 1.33) 6.15 (1.95) 1.60 (1.15) (1.11, 2.10)
CRP (mg/dL) 3.05 (2.92) 0.50 (0.56) (0.31, 0.69) 2.54 (2.45) 1.10 (1.38) (0.42, 1.78) 3.24 (2.70) 0.56 (0.58) (0.36, 0.75) 2.89 (2.92) 1.15 (1.24) (0.61, 1.68)
ESR (mm/hour)* 47.93 (23.18) 22.60 (15.36) (14.09, 31.11) 39.11 (27.51) 19.22 (16.42) (6.60, 31.85) 49.06 (26.33) 24.94 (20.27) (14.14, 35.74) 46.18 (35.98) 26.36 (22.86) (11.00, 41.72)
  1. *Numbers of patients: n = 15 for abatacept plus MTX and n = 9 for MTX alone for SDAI, and n = 16 for abatacept plus MTX and n = 11 for MTX alone for CDAI; as-observed data for patients with data at baseline, month 6 and month 12. CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28 Disease Activity Score using 28 joint counts, EGA evaluator’s global assessment, ESR erythrocyte sedimentation rate, MTX methotrexate, PGA Patient Global Assessment, SDAI Simplified Disease Activity Index, SJC swollen joint count, TJC tender joint count, VAS visual analog scale